Resmed (ASX:RMD) reported Friday fiscal second-quarter earnings of $2.43 per diluted share on a non-GAAP basis, up from $1.88 per diluted share a year earlier.
Analysts polled by Visible Alpha expected $2.32 per diluted share.
Revenue for the three months ended Dec. 31, 2024, rose 10% to $1.28 billion from $1.16 billion a year earlier. Analysts surveyed by Visible Alpha expected $1.27 billion.
The board declared a quarterly cash dividend of $0.53 per share, with a record date of Feb. 13, payable on March 20. This is up from the previously reported period's dividend of $0.48.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.